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Abstract 
Tissue factor (TF) is a transmembrane receptor and cofactor of factor (F) VII/VIIa. The 
TF/FVIIa complex activates the coagulation cascade. It is highly expressed in pancreatic 
ductal adenocarcinoma (PDAC). Elevated levels of circulating, tumor-derived TF+ 
extracellular vesicles are associated with venous thromboembolism in pancreatic cancer. 
Since hemostasis requires TF, systemic inhibition of TF to reduce VTE risk would lead to 
severe bleeding. Previous studies reported that the Kirsten rat sarcoma viral oncogene 
homolog (KRAS) and mammalian target of rapamycin (mTOR) pathways regulate TF 
gene expression in human cancer cells. Therefore, we hypothesized that blocking KRAS 
and mTOR would reduce TF gene expression in PDAC. We examined the effect of the 
KRAS inhibitor stabilized alpha helices of son of sevenless 1 (SAH-SOS1A) and the 
mTOR inhibitor sapanisertib on TF gene expression in two high-TF expressing PDAC cell 
lines HPAF-II and BxPC-3. We hypothesized that 1) inhibition of KRAS with SAH-SOS1A 
would reduce TF expression in HPAF-II cells, which contain a constitutively active mutant 
KRAS, to a greater extent than in BxPC-3, which contains wild-type KRAS, and that 2) 
mTOR inhibition with sapanisertib would reduce TF expression in both cell lines. HPAF-
II and BxPC-3 were treated for 48 hours with either SAH-SOS1A or sapanisertib. Cell 
viability and growth was measured with a resazurin uptake assay, and total protein 
concentration was determined using Pierce BCA and DC assays to examine if the 
inhibitors were toxic. Levels of cellular TF activity were determined using a one-stage 
coagulation assay. Our study yielded an unexpected result: both inhibitors were toxic to 
the cells and reduced cell viability, total protein, and TF activity. Taken together, these 
preliminary studies suggest that the decrease in TF activity in cells treated with either 
inhibitor is due to cell death rather than a selective inhibition of TF gene expression.  
 
Introduction 
Tissue factor (TF) is a transmembrane glycoprotein receptor that binds the serine 
protease factor VIIa (FVIIa) to initiate the extrinsic blood coagulation cascade.1 The 
TF:FVIIa complex also activates a variety of different cell-signaling pathways that 
enhance tumor growth and metastasis via cleavage of protease-activated receptors 
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(PARs).2–4 Aberrant expression of TF has been detected in a range of malignancies5 and 
is associated with cancer stage and poor prognosis.6,7  
Pancreatic ductal adenocarcinomas (PDAC) express very high levels of TF.4,7–9 
PDAC accounts for approximately 85-90% of pancreatic cancers8,10 and has a 5-year 
survival rate of ~8%.4,8 Pancreatic cancer also has one of the highest rates of venous 
thromboembolism (VTE) (5-26%),11–15 a leading cause of mortality in cancer patients.16–
22 Furthermore, elevated VTE rates are observed in pancreatic cancer patients with high 
TF expression compared to those with low TF expression.4,23 
Given these observations, targeting TF may reduce VTE and improve the survival 
of patients with pancreatic cancer. However, because TF is crucial for hemostasis, 
systemic inhibition of TF would be accompanied by an increased bleeding risk. Instead, 
we hypothesize that reducing TF expression by targeting intracellular signaling pathways 
that regulate TF gene expression in pancreatic tumors would reduce VTE without 
bleeding in PDAC patients. This project sought to examine the effect of inhibiting two 
major signaling pathways involved in cancer on TF gene expression in two human 
pancreatic cancer cell lines. These pathways were 1) the Kirsten rat sarcoma viral 
oncogene homolog (KRAS) pathway, and 2) the mammalian target of rapamycin (mTOR) 
pathway. We used HPAF-II and BxPC-3 cell lines, both of which express high levels of 
TF.9,24 
The first target is KRAS, which activates the rapidly accelerated fibrosarcoma 
(RAF) kinase – mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) – extracellular 
signal-regulated kinase (ERK) pathway through sequential phosphorylation.25 The 
functional RAS/ERK pathway plays a critical role in promoting cell growth and 
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proliferation, and therefore when mutated is often implicated as a driver of cancer 
progression.10,25–27 
KRAS activating mutations occur in ~94% of pancreatic cancers.25,28 KRAS 
activation in the human colorectal carcinoma cell lines HCT116 and DLD-1 is associated 
with increased TF expression.17 A retrospective study also revealed an association 
between KRAS mutation and VTE risk in patients with metastatic colon cancer, and 
suggested that the increased VTE risk may be related to elevated TF expression.29  
We determined the effect of stabilized alpha helices of son of sevenless 1 (SAH-
SOS1A), a peptide inhibitor of both wild-type (WT) and mutant KRAS,26 on TF expression 
in HPAF-II and BxPC-3 cells. SAH-SOS1A binds to the KRAS binding pocket with high 
affinity and inhibits KRAS association with GTP while also preventing KRAS from 
interacting with wild-type SOS1,26 a guanine nucleotide exchange factor that serves as 
the catalyst for GTP activation of KRAS.26,27,30 We hypothesized that inhibition of KRAS 
would lead to a greater reduction in TF in HPAF-II, which contains a mutant KRAS with 
increased activity (KRAS G12D mutant24), than in BxPC-3 (KRAS WT9). This project also 
investigated the effect of SAH-SOS1A on cell viability and total protein concentration, and 
examined the phosphorylation of ERK, a downstream effector of KRAS, to confirm KRAS 
inhibition.  
The second part of this project focused on mTOR, a downstream serine/threonine 
kinase essential to the PI3K/AKT/mTOR signaling cascade.31 mTOR is a key regulator of 
cell growth and survival, metabolism, and migration,33–36 but its overexpression has been 
implicated in the progression of several cancers.36 Studies have observed mTOR 
activation in 15-75% of PDAC.35,37–39 
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We examined the effect of the mTOR inhibitor sapanisertib (also known as 
MLN0128, TAK-228, and INK 128) on TF gene expression in HPAF-II and BxPC-3. 
Sapanisertib is a drug that is currently being evaluated in clinical trials to treat patients 
with various cancers,34 including pancreatic neuroendocrine tumors (PNET).40 It inhibits 
the kinase activity of mTOR by competitively binding to the ATP site in the mTOR kinase 
domain.34,41–44 It has been shown that inhibition of mTOR with sapanisertib reduces 
mRNA levels and activity of TF in BON, a human PNET cell line, both in vitro and in vivo.41 
This suggests that mTOR is an upstream regulator of TF in PNET.41 Therefore, we 
expected that sapanisertib would yield similar regulatory effects on TF expression in our 
PDAC cell lines. We also investigated its effect on cell viability and total protein 
concentration. 
Overall, our goal was to determine if inhibition of the 1) KRAS and 2) mTOR 




Cell Culture  
HPAF-II and BxPC-3 cells were cultured in T150 flasks with MEM (Thermo Fisher 
Scientific, Waltham, MA, Cat#11095-080) and RPMI 1640 (Thermo Fisher Scientific, 
Cat#11875-093), respectively, and were maintained at standard conditions (5% CO2, 
37ºC). Both media contained 10% fetal bovine serum (FBS) (Omega Scientific, Tarzana, 
CA, Cat#FB-02) and 1% Antibiotic-Antimycotic (Thermo Fisher Scientific, Cat#15240-
062). Cells were detached through trypsinization when they neared 70-80% confluence 
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and were added to new T150 flasks, where they were maintained for use in the 
experiments. All cells were treated with inhibitors the day after they were plated.       
 
Inhibitors 
SAH-SOS1A peptide (EMD Millipore, Temecula, CA, Cat#538092) was first mixed 
in Tris buffer (50 mM Tris, 150 mM NaCl, pH 8.0) and the solution was further mixed with 
a Q700 sonicator (QSONICA, Melville, NY). The SAH-SOS1A stock solution was further 
diluted with the appropriate serum-free medium to concentrations of 0, 1.25, 2.5, 5, 10, 
20, 40, and 80 µM. To inhibit mTOR, a 10 mM stock solution of sapanisertib (MedKoo 
Biosciences, Research Triangle Park, NC) in DMSO was prepared and diluted to 0, 5, 10, 
20, 40, 80, and 160 nM in medium. 
 
Resazurin Cell Viability Assay 
For assessment of cell proliferation and viability at different concentrations of 
inhibitors, 104 cells per well were seeded into 96-well plates. Cells were incubated at 37ºC 
for 48 hours in the appropriate media with varying inhibitor concentrations. The culture 
supernatant was then removed and cells were incubated for 4 hours in Resazurin (R&D 
Systems), a blue fluorescent indicator dye that is taken up by viable cells and 
metabolically reduced to the highly fluorescent form, resorufin.45 Fluorescence was 
measured with a SpectraMax® M5 Microplate Reader (Molecular Devices, San Jose, CA) 
at excitation wavelengths of 544 nm and emission wavelengths of 590 nm. 
 
Protein Assay Sample Preparation  
To determine total protein concentrations of HPAF-II and BxPC-3 cell lysates after 
treatment with SAH-SOS1A, 1.5 x 105 cells per well were seeded into 6-well plates. 
 7 
Duplicate wells were dosed with each concentration of SAH-SOS1A the following day, and 
plates were incubated at 37ºC for 48 hours. Cells were then washed with PBS, and RIPA 
lysis buffer (MilliporeSigma, Burlington, MA, Cat#20-188) containing a protease inhibitor 
cocktail (Roche, Cat#11697498001) and Phosphatase Inhibitor Cocktail A (Santa Cruz 
Biotechnology, Cat#sc-45044) was added. After 15 minutes, cells were transferred to 
tubes and incubated on ice for another 30 minutes. These were sonicated with 
approximately 29 kJ and centrifuged at 10,000 x g for 10 minutes at 4ºC, and the PierceTM 
bicinchoninic acid (BCA) protein assay (Thermo Fisher Scientific, Cat#23227) was used 
to determine protein concentrations of the lysates. Absorbances of the standard and 
sample solutions were measured at 562 nm using a SpectraMax® M5 to give the total 
protein content in each sample. 
To determine total protein concentrations of cell lysates after treatment with 
sapanisertib, 3 x 105 cells per well were seeded into 6-well plates. The following day, 
triplicate wells were dosed with each concentration of sapanisertib. After a 48-hour 
incubation with the inhibitor at 37ºC, culture supernatant was removed. Each well was 
scraped and cell contents were collected into separate 1.5 milliliter tubes with 1 mL of 
phosphate-buffered saline (PBS). Cells were then disrupted by sonication with 
approximately 25 kJ total. Protein concentrations of sonicated cell samples were 
determined using the DC Protein Microplate Assay (Bio-Rad). Prepared bovine serum 
albumin standards (Thermo Fisher Scientific) were used to create a standard curve. Five 
microliters of standards or sonicated samples and 225 µL of assay reagents were added 
to each well of a 96-well microplate. Samples were incubated for 15 minutes at room 
 8 
temperature. Absorbances of the standard and sample solutions were measured at 750 
nm using a SpectraMax® M5 to give the total protein content in each sample. 
 
One-Stage Coagulation Assay 
A metal ball was placed into each cuvette in the STart 4 Hemostasis Analyzer 
(Diagnostica Stago, Parsippany, NJ). Fifty microliters of Pacific Hemostasis Coagulation 
Control, Normal Level 1 plasma (Thermo Fisher Scientific, Cat#100595) in DEPC water 
and 50 µL of each sonicated cell sample were added to every cuvette, and an 
electromagnetic field was applied to oscillate the metal ball. Fifty microliters of 25 mM 
CaCl2 in PBS were added to each cuvette to initiate clotting, and the times required for 
coagulation (which stopped movement of the ball), were recorded as clotting times. TF 
concentrations were determined using a standard curve produced with various 
concentrations of Innovin (recombinant TF) (Siemens, Malvern, PA). 
 
Statistical Analysis 
Bars are presented as mean ± standard deviation. The Shapiro-Wilk test was used 
to determine normality. For multiple comparisons, either the one-way ANOVA with 
Dunnett’s multiple comparison test or the Kruskal-Wallis test with Dunn’s multiple 
comparison test was used according to the normality of the data distributions. These 
statistical analyses were performed with GraphPad PRISM version 8.4.0 (GraphPad 






HPAF-II and BxPC-3 were incubated for 48 hours in various concentrations of each 
inhibitor. We measured 4 main parameters: 1) cell viability through visual inspection, 2) 
cell viability using the resazurin assay, 3) total protein concentration, and 4) cellular TF 
activity. For all parameters, the responses of cells treated with the inhibitor were 
compared to that of cells treated with vehicle. First, the presence of visible cell death 
would indicate that the inhibitors are cytotoxic. Second, in the resazurin assay, a decrease 
in fluorescence compared to untreated cells indicates that the inhibitor reduces cell 
viability. Third, a decrease in total protein concentration of inhibitor-treated cells 
compared to that of untreated cells indicates a cytotoxic effect on the cells. Fourth, a 
decrease in TF activity with no effect on cell viability would indicate a selective inhibition 
of TF expression whereas a decrease in both TF activity and cell viability would indicate 
that the decrease in TF activity is secondary to cell death.   
1) Effect of the KRAS inhibitor SAH-SOS1A on different parameters in HPAF-II and 
BxPC-3 cells.  
We treated cells with SAH-SOS1A to examine whether the KRAS pathway 
contributes to TF gene expression in our PDAC cell lines. Substantial death of both HPAF-
II and BxPC-3 cells was visible in the 6-well plate cells treated with 40 µM and 80 µM 
SAH-SOS1A, and almost all BxPC-3 cells observed at 80 µM were non-adherent. This 
suggests that increasing concentrations of SAH-SOS1A were toxic to these cells. In 
contrast to these visual observations, the resazurin assays showed only small, though 
still significant, differences in fluorescence, with no concentration-dependence to these 
changes (Figures 1A and 1B). We observed a decrease in total protein concentration and 
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TF activity in both cell lines with 40 µM and 80 µM SAH-SOS1A treatment (Figures 1C-
1F). To independently analyze if the inhibitor was cytotoxic, cells were incubated with 
SAH-SOS1A in 6-well plates and lysates were analyzed by western blotting 
(Supplementary Materials, Methods). Phosphorylated ERK or GAPDH were greatly 
reduced by western blotting in BxPC-3 lysates treated with 40 µM SAH-SOS1A (Figure 
S1B).  























































































































Figure 1. Effect of SAH-SOS1A on cell viability, protein levels, and cellular TF activity. (A, B) Fluorescence after 48-
hour SAH-SOS1A treatment, n=8. Bars represent mean ± standard deviation, and asterisks label data with a significant 
difference compared to untreated: * p < 0.05 and ** p < 0.01. Total protein in HPAF-II (C) and BxPC-3 (D), and cellular 
TF activity of HPAF-II (E) and BxPC-3 (F) are shown. Values are shown relative to that of untreated (0 μM SAH-SOS1A) 
cells, n=2. Statistical analysis could not be performed with total protein or TF activity because only 2 independent 
experiments were performed.  
 
2) Effect of the mTOR inhibitor sapanisertib on different parameters in HPAF-II and 
BxPC-3 cells. 
We next sought to determine if mTOR regulates TF expression in two PDAC cell 
lines by examining the effect of sapanisertib treatment on the 4 parameters described 
above. After cells were treated with sapanisertib, no HPAF-II cell death was visually 
observed in the 96-well plate used for the resazurin assay, while some death of BxPC-3 
cells was seen in the 96-well plate following treatment with 80 nM and 160 nM 
sapanisertib. Interestingly, the resazurin assay showed a concentration-dependent 
reduction in cell viability of HPAF-II and BxPC-3 cells treated with sapanisertib (Figures 
2A and 2 B). The assay also produced a higher fluorescence signal for BxPC-3 cells than 
for HPAF-II cells, which reflects the faster growth of BxPC-3. Sapanisertib also 
concentration-dependently reduced total protein in HPAF-II and BxPC-3 cells (Figures 2C 
and 2D). Interestingly, sapanisertib decreased TF expression in HPAF-II cells in a 
concentration-dependent manner, but had no effect on TF activity in BxPC-3 cells 




Figure 2. Effect of sapanisertib on cell viability, protein levels, and cellular TF activity. Fluorescence of HPAF-II (A) and 
BxPC-3 (B) are shown, n=8. Total protein in HPAF-II (C) and BxPC-3 (D), and cellular TF activity of HPAF-II (E) and 
BxPC-3 (F) are shown. Bars represent mean ± standard deviation, n=3. Asterisks label data with a significant difference 
compared to untreated: * p < 0.05, ** p < 0.01, *** p < 0.001, and **** p < 0.0001. 
 
Discussion  
Our main goal was to examine the effect of KRAS and mTOR inhibitors on TF gene 
expression in two human pancreatic cancer cell lines, HPAF-II and BxPC-3. We found 
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that both inhibitors induced cell death of the PDAC cell lines. Therefore, we were unable 
to assess the roles of KRAS and mTOR in TF gene expression using these inhibitors 
independently of the effect of cell death. Nevertheless, we made some interesting 
observations during these studies.  
First, treatment of HPAF-II and BxPC-3 with KRAS inhibitor SAH-SOS1A has a 
cytotoxic effect on the cells. While SAH-SOS1A did yield a reduction in cellular TF activity 
at the two highest concentrations, 40 µM and 80 µM, the concentration-dependent 
decrease in total protein concentrations in both cell lines suggests that the lower TF 
activity levels are largely attributed to cells being killed by the high inhibitor concentrations, 
which we had visually observed. This was also reflected in the western blot of BxPC-3 
lysates when we attempted to determine if SAH-SOS1A inhibited KRAS and did not 
observe a signal for any of the probed targets in 40 µM-treated BxPC-3 (Figure S1B and 
S1D). The absorbance of this lysate sample fell near the edge of the standard curve of 
the protein assay, which makes the accuracy of protein concentration of the 40 µM 
sample questionable.  
It is unclear why the results of the resazurin viability assays (96-well plates) were 
inconsistent with the decrease in cell viability as seen with our visual observation of cell 
death (6-well plates), the total protein concentration, the TF activity, and the western blot. 
It is possible that cells were more confluent in the 96-well plates and were therefore better 
protected against SAH-SOS1A than the cells in the 6-well plates, which we used for the 
protein assay, TF activity assay, and western blot. Another possible explanation is that 
SAH-SOS1A may interfere with the resazurin assay. This can be confirmed in a future 
experiment by adding the inhibitor to cells and immediately beginning the resazurin assay.   
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Given these results, we cannot separate any reduction in KRAS-dependent TF 
expression from that resulting from the cytotoxic effects of 48-hour SAH-SOS1A treatment. 
The group that created SAH-SOS1A showed that the peptide inhibited KRAS kinase 
activity through western blot detection of a variety of targets, including phosphorylated 
ERK, but only treated their cells for 4 hours.26 However, our preliminary study with a 48-
hour treatment of this inhibitor showed that SAH-SOS1A had no effect on HPAF-II 
fluorescence in the resazurin assay, and it even increased fluorescence of BxPC-3 
(Figures S2A and S2B). SAH-SOS1A also did not affect protein levels or cellular TF 
activity in either cell line (Figures S2C and S2C). Therefore, this repeat experiment was 
completed to verify those results. It is not known why our two experiments gave different 
results. Conducting a time-course experiment with SAH-SOS1A, and with other KRAS 
inhibitors as well, may help shed a light on a time- and concentration-dependent effect of 
KRAS inhibition on TF gene expression in these cell lines.  
The second focus of this study was the inhibition of mTOR by sapanisertib. 
Sapanisertib decreased cell viability of both HPAF-II and BxPC-3, as measured by 
reduced fluorescence in the resazurin assays and in decreased total protein 
concentrations. Therefore, the reduced TF activity in HPAF-II is likely attributed to an 
increase in cell death. We speculate that the resazurin and protein assays are more 
sensitive than our visual inspection of cells in culture. Some cells may have appeared 
adherent, but in response to toxicity may have exhibited morphological or metabolic 
changes that we did not visually detect.  
On the other hand, the cytotoxic effect measured in the BxPC-3 cell lysates is 
consistent with the apparent death of BxPC-3 cells treated with 80 nM and 160 nM 
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sapanisertib. Our data is consistent with a previous study that showed that sapanisertib 
treatment reduced cell survival of two other human PDAC cell lines, PANC-1 and MIA 
PaCa-2.46 However, sapanisertib-treated BxPC-3 cells yielded unexpected outcomes that 
are in contrast to the study of our collaborator, which showed TF suppression in mTOR-
inhibited BON.41 We observed a reduction in BxPC-3 cell viability but relatively constant 
cellular TF activity with sapanisertib treatment, which suggests that the fewer surviving 
cells demonstrated an enhanced level of TF activity equal to that of the more numerous 
untreated cells. It is possible that sapanisertib actually decreases levels of the TF protein, 
but increases its activity by some form of post-translational modification. The reason for 
enhanced cellular TF activity in BxPC-3 at higher concentrations of sapanisertib requires 
further investigation, such as through western blotting to measure the amount of TF 
protein.  
Enhanced BxPC-3 cellular TF activity with sapanisertib treatment despite cell 
death may possibly also occur through mechanisms similar to those that occur with 
inhibition of mTOR by rapamycin. It has been shown that rapamycin enhances thrombus 
formation in vivo.47 Clinical case reports and reviews have also described thrombotic 
events in patients after they received rapamycin either through drug-eluting coronary 
stents,48,49 or after kidney50 and liver (with a higher, albeit insignificant, hepatic artery 
thrombosis incidence)51 transplants.52 However, further clinical studies are required to 
determine a causative effect of rapamycin on thrombosis. Guba et al.53 have also 
described a relationship between rapamycin treatment and enhanced TF expression in 
human umbilical vein endothelial cells stimulated with VEGF in vitro, L3.6pl pancreatic 
tumors, CT-26 colon cancer tumors, and A-mel 3 melanoma tumors in vivo. Other studies 
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have shown this relationship in human aortic endothelial cells in vitro54 and A549 non-
small cell lung cancer tumors in vivo.55 Rapamycin has also been found to stimulate TF 
gene expression, although not activity, in human vascular smooth muscle cells.56  
Guba et al.53 proposed that rapamycin both reduces signaling by the 
PI3K/Akt/mTOR pathway, which they suggested is a negative regulator of TF expression, 
and activates a TF-enhancing MAPK pathway especially in the presence of VEGF. Guha 
and Mackman57 also found that the activated PI3/Akt pathway restricts the induction of 
TF gene expression by lipopolysaccharide (LPS), and inhibition of the pathway therefore 
increases LPS-induced TF gene expression. It is possible that sapanisertib had a similar 
mTOR-downregulating and KRAS-upregulating effect on BxPC-3 in this study, and 
therefore tipped the balance between KRAS and mTOR to induce TF gene expression. 
To confirm the results of this present study, additional investigations with rapamycin-
mediated inhibition of mTOR inhibition should be performed. Furthermore, mTOR 
inhibition should be verified with western blot detection of known mTOR downstream 
effectors.  
It is possible that in BxPC-3 and HPAF-II, TF is more strongly regulated by 
pathways not examined in this study. In future studies, an effective chemical inhibitor or 
CRISPR-Cas9 could be used to knock down these genes in cells, such as BxPC-3 and/or 
HPAF-II. Investigation of TF mRNA levels through RT-PCR could also provide information 
about changes in gene expression. Such experiments would further elucidate the 
relationship between the knocked down gene and TF gene expression in our search to 
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Figure S1. Western blots and densitometry analysis show levels of p-ERK and GAPDH in HPAF-II (A, C) and BxPC-3 
(B, D). Cells were lysed after 48-hour treatment with SAH-SOS1A. GAPDH densitometry shows average GAPDH area 
under curve values relative to that of untreated cells (0 µM SAH-SOS1A), n=2.  






























































Figure S2. First experiment with SAH-SOS1A. Fluorescence of HPAF-II (A) and BxPC-3 (B) after 48-hour incubation 
with different concentrations of SAH-SOS1A at 37º, n=8. Protein concentrations of HPAF-II (C) and BxPC-3 (D), and 
cellular TF activity of HPAF-II (E) and BxPC-3 (F). Bars for total protein and TF activity show mean ± standard deviation, 








































































































































































SDS-PAGE of Cell Lysates Treated with SAH-SOS1A 
For electrophoresis, SDS sample buffer (Invitrogen, Carlsbad, CA, Cat#NP0007) 
with 5% β-mercaptoethanol was added to cell lysates, which were heated to 95ºC for 10 
minutes. Samples (3.1 µg protein/well for HPAF-II; 1.2 µg protein/well for BxPC-3) were 
loaded onto 4-20% gradient Mini-PROTEAN® TGXTM gels (BioRad Laboratories, 
Hercules, CA, Cat#456-1093) with Precision Plus ProteinTM KaleidoscopeTM Prestained 
Protein Standards (BioRad Laboratories, Hercules CA, Cat#161-0375) as a marker for 
molecular weight. Electrophoresis in Tris/Glycine/SDS buffer (BioRad Laboratories, 
Cat#161-0732) was used to separate proteins.  
Western Blotting 
Proteins were transferred to polyvinylidene difluoride membranes (MilliporeSigma, 
Cat#IPFL00010) and blocked with protein-free blocking buffer (Thermo Fisher Scientific 
Cat#23227). Membranes were probed using Phospho-p44/42 (ERK1/2) (Thr202/Tyr204) 
(D13.14.4E) XP® Rabbit mAb (Cell Signaling Technologies, Danvers, MA, Cat#4370), 
p44/42 (ERK1/2) (137F5) Rabbit mAb (Cell Signaling Technologies, Cat#4695) and goat 
anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) polyclonal antibody (Abcam, 
Cambridge, MA, USA, ab9483), which were diluted 1:2000, 1:1000, and 1:200, 
respectively, in blocking buffer. Blots were then washed with Tris-buffered saline with 
0.1% Tween20 (TBS-T) and incubated with IR Dye® 680RD goat anti-rabbit IgG (LI-COR, 
Lincoln, NE, Cat#926-68071) or IRDye® 800CW Donkey anti-Goat IgG (LI-COR, 
Cat#926-32214), each diluted to 1:10k in blocking buffer. Blots were developed with an 
Odyssey imaging system (LI-COR).  
